Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 4.42% is 86% above its 1-year average of 2.38%, near the high end of its 1-year range (0.49%–4.42%).
As of the fiscal period ended Tuesday, June 30, 2026. 60.39% above its 12-month average of 2.76%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 4.42%.
RETURN ON EQUITY (ROE)
4.42%
RETURN ON EQUITY (ROE) AVG TTM
2.76%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+60.39%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · FINANCIAL SERVICES
10.14%
median of 358 covered companies
CURRENT VS SECTOR MEDIAN
-56.39%
vs the sector median at left
Drugs Made In America Acquisition Corp. Ordinary Shares
Market Cap
$264.62M
Return on Equity (ROE)
4.42%
TTM Avg
2.76%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$266.32M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.30M
Return on Equity (ROE)
2.18%
TTM Avg
0.24%
3Y Avg
0.16%
5Y Avg
0.16%
Market Cap
$261.73M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.51M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.19M
Return on Equity (ROE)
1.17%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$260.97M
Return on Equity (ROE)
2.16%
TTM Avg
30.37%
3Y Avg
103.36%
5Y Avg
69.17%
Market Cap
$269.77M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$270.60M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) | $264.62M | 4.42% | 2.76% | N/A | N/A |
| Thunder Bridge Capital Partners V L (TBCVU)vs › | $266.32M | N/A | N/A | N/A | N/A |
| Cantor Equity Partners V, Inc. Class A Ordinary Shares (CEPV)vs › | $262.30M | 2.18% | 0.24% | 0.16% | 0.16% |
| AMR Resources Acquisition Corp Class A Ordinary Shares (AMAC)vs › | $261.73M | N/A | N/A | N/A | N/A |
| Art Technology Acquisition Corp. (ARTC)vs › | $261.51M | N/A | N/A | N/A | N/A |
| GigCapital8 Corp. (GIW)vs › | $261.19M | 1.17% | 0.00% | 0.00% | 0.00% |
| FACT II Acquisition Corp (FACT)vs › | $260.97M | 2.16% | 30.37% | 103.36% | 69.17% |
| Cartesian Growth Corp. Iv (CGCF)vs › | $269.77M | N/A | N/A | N/A | N/A |
| Freedom Metals Acquisition Corp. (FDMM)vs › | $270.60M | N/A | N/A | N/A | N/A |
| First National Corporation (FXNC)vs › | $270.87M | 11.20% | 6.84% | 9.37% | 9.46% |
ROE
4.4%
ROA
4.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 4.42% |
| 2026-03-31 | 2.84% |
| 2025-12-31 | 2.55% |
| 2025-09-30 | 2.49% |
| 2025-06-30 | 1.49% |
| 2025-03-31 | 0.49% |
